Table 1.
Baseline characteristics of the study groups.
| Variable | bLf group (n = 78) | Placebo group (n = 78) | p |
|---|---|---|---|
| Age, mean | 4.28 ± 3.3 | 4.06 ± 2.6 | 0.6 |
| Male sex, n (%) | 30 (38.5) | 44 (56.4) | 0.03 |
| Diagnosis | |||
| Upper respiratory tract infection, n (%) | 42 (53.8) | 33 (42.3) | 0.2 |
| Lower respiratory tract infection, n (%) | 24 (30.8) | 37 (47.4) | 0.03 |
| Urine tract infection, n (%) | 12 (15.4) | 8 (10.3) | |
| Antibiotic | |||
| Penicillins n (%) | 51 (65.4) | 42 (53.8) | 0.1 |
| Cephalosporins, n (%) | 20 (25.6) | 21 (26.9) | 0.9 |
| Clindamycin, n (%) | 1 (1.3) | 0 | 1.0 |
| Macrolides, n (%) | 6 (7.7) | 15 (19.2) | 0.04 |
| Duration of treatment with antibiotics, mean ± SD days | 8.6 ± 2.8 | 9.2 ± 4.3 | 0.3 |
bLf, bovine lactoferrin.